From their announcement in January 2015:
Genetic Technologies (ASX:GTG) has announced that up to six new US breast centres will start offering the company’s BREVAGenplus breast cancer risk assessment tool this calendar quarter. The company expects a number of new breast diagnosis, imaging and treatment centres to pick up the test later the year, and so is anticipating an acceleration of sales growth starting in the second half.
We can only hope this eventuates as well!
From their announcement in January 2015: Genetic Technologies...
Add GTG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.671M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| GTG (ASX) Chart |
Day chart unavailable